scispace - formally typeset
Open AccessJournal ArticleDOI

Novel Chimpanzee/Human Monoclonal Antibodies That Neutralize Anthrax Lethal Factor, and Evidence for Possible Synergy with Anti-Protective Antigen Antibody

Reads0
Chats0
TLDR
Two chimpanzee Fabs reactive with lethal factor of anthrax toxin were isolated and converted into complete monoclonal antibodies with human γ1 heavy-chain constant regions, and both LF10E and LF11H recognize domain I of LF, which is responsible for binding to PA.
Abstract
Three chimpanzee Fabs reactive with lethal factor (LF) of anthrax toxin were isolated and converted into complete monoclonal antibodies (MAbs) with human γ1 heavy-chain constant regions. In a macrophage toxicity assay, two of the MAbs, LF10E and LF11H, neutralized lethal toxin (LT), a complex of LF and anthrax protective antigen (PA). LF10E has the highest reported affinity for a neutralizing MAb against LF (dissociation constant of 0.69 nM). This antibody also efficiently neutralized LT in vitro, with a 50% effective concentration (EC50) of 0.1 nM, and provided 100% protection of rats against toxin challenge with a 0.5 submolar ratio relative to LT. LF11H, on the other hand, had a slightly lower binding affinity to LF (dissociation constant of 7.4 nM) and poor neutralization of LT in vitro (EC50 of 400 nM) and offered complete protection in vivo only at an equimolar or higher ratio to toxin. Despite this, LF11H, but not LF10E, provided robust synergistic protection when combined with MAb W1, which neutralizes PA. Epitope mapping and binding assays indicated that both LF10E and LF11H recognize domain I of LF (amino acids 1 to 254). Although domain I is responsible for binding to PA, neither MAb prevented LF from binding to activated PA. Although two unique MAbs could protect against anthrax when used alone, even more efficient and broader protection should be gained by combining them with anti-PA MAbs.

read more

Citations
More filters
Journal ArticleDOI

An overview of anthrax infection including the recently identified form of disease in injection drug users.

TL;DR: While antibiotics are the mainstay of anthrax treatment, use of adjunctive therapies such as anthrax toxin antagonists are a consideration and Prompt surgical therapy appears to be important for successful management of injectional anthrax.
Journal ArticleDOI

Monoclonal antibody therapies against anthrax.

TL;DR: This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.
BookDOI

Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity

TL;DR: An in-depth analysis of the scientific necessity of chimpanzees for NIH-funded biomedical and behavioral research concluded that chimpanzees are necessary for research discoveries and to gauge the safety and efficacy of new medicines.
Journal ArticleDOI

Antibodies for biodefense

TL;DR: Capacities and limitations of antibodies for use in biodefense are discussed, and are generally applicable to the field of infectious diseases.
Journal ArticleDOI

A comparison of binding surfaces for SPR biosensing using an antibody-antigen system and affinity distribution analysis.

TL;DR: This work uses an antibody-antigen interaction as a model system and studies the activity, thermodynamic and kinetic binding parameters, and heterogeneity of surface sites produced with different commonly used sensor surfaces, at different total surface densities and with direct immobilization or affinity capture.
References
More filters
Journal ArticleDOI

Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor

TL;DR: It is shown that LF is a protease that cleaves the amino terminus of mitogen-activated protein kinase kinases 1 and 2 and that this cleavage inactivates MAPKK1 and inhibits the MAPK signal transduction pathway.
Journal ArticleDOI

Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

TL;DR: Clinical presentation and course of cases of bioterrorism-related inhalational anthrax, in the District of Columbia, Florida, New Jersey, and New York, are described; survival of patients was markedly higher than previously reported.
Journal ArticleDOI

Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

TL;DR: It is shown here that EF is an adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1] produced by Bacillus anthracis in an inactive form and nearly equals that of the most active known cyclase.
Journal ArticleDOI

Anthrax toxin: receptor binding, internalization, pore formation, and translocation.

TL;DR: Advances in understanding the entry process include insights into how PA recognizes its two known receptors and its ligands, LF and EF; how the PA:receptor interaction influences the pH-dependence of pore formation; and how the pore functions in promoting translocation of LF andEF across the endosomal membrane.
Journal ArticleDOI

The human immunoglobulin VH repertoire

TL;DR: A complete map of the human immunoglobulin VH locus on chromosome 14 has been constructed and the organization of the locus, its polymorphism and the repertoire it encodes are reviewed.
Related Papers (5)